# Valiant Organics share price today (Valiant Organics Ltd, NSE: VALIANTORG)

> Valiant Organics share price today: ₹419.95 at the NSE close on 3 November 2026, up 39.7% in a year. Valiant Organics (NSE: VALIANTORG) is worth ₹1,177 crore, trades at a P/E of 23.3 and has closed between ₹207.55 and ₹478.35 over the past 52 weeks. > Valiant Organics Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. VALIANTORG · Chemicals - Organic · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/valiant-organics-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹419.95 (+39.7% in a year)
- P/E: 23.3× (higher than 53% of the last 7.1 years)
- Revenue (Jun 2026): ₹232 Cr (+13.7% on a year ago)
- Profit (Jun 2026): ₹29.0 Cr (+262.5% on a year ago)
- Operating margin: 18.0% (+6.0 points on a year ago)
- ROCE: 5%, FY26

Biggest thing to watch: the price has already been rising for 9 weeks, so timing is the risk more than the business. ## What is the Valiant Organics share price today? Valiant Organics Ltd's share price was ₹419.95 at the close on 3 November 2026. It has been rising for 9 weeks. That is 26.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹208 and ₹478, and at that close it sat 78% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 11 weeks in a row. Over the last 10 years the share price moved +218% while the NIFTY 500 moved +192%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Valiant Organics this quarter? Three changes stood out: best operating margin in 13 quarters, highest quarterly profit in 13 quarters and highest quarterly revenue in 13 quarters. 1. Best operating margin in 13 quarters Operating margin was 18% in the June 2026 quarter, against 12% a year earlier. 2. Highest quarterly profit in 13 quarters Profit of ₹29 crore in the June 2026 quarter is the highest of the last 13 quarters. 3. Highest quarterly revenue in 13 quarters Revenue of ₹232 crore in the June 2026 quarter is the highest of the last 13 quarters. ## What are Valiant Organics' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Valiant Organics reported revenue of ₹232 crore, up 13.7% from ₹204 crore a year earlier, and a profit of ₹29.0 crore, up 262.5% from ₹8.00 crore. ### Valiant Organics results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹232 crore | ₹204 crore | +13.7% |
| Profit | ₹29.0 crore | ₹8.00 crore | +262.5% |
| Earnings per share | ₹10.36 | ₹2.93 | +253.6% |
| Operating margin | 18.0% | 12.0% | +6.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 10 November 2023, about July to September 2023; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Valiant Organics share price history? Valiant Organics closed at ₹419.95 on 3 November 2026, up 39.7% from ₹300.70 a year earlier (31 October 2025) and down 68.4% over five years. Its highest weekly close since October 2016 was ₹1,844.95 on 6 November 2020. ### Valiant Organics share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹412.75 | +1.7% |
| 1 month ago · 1 Oct 2026 | ₹478.35 | −12.2% |
| 6 months ago · 30 Apr 2026 | ₹270.70 | +55.1% |
| 1 year ago · 31 Oct 2025 | ₹300.70 | +39.7% |
| 3 years ago · 3 Nov 2023 | ₹439.10 | −4.4% |
| 5 years ago · 4 Nov 2021 | ₹1,329.40 | −68.4% |
| 10 years ago · 4 Nov 2016 | ₹256.18 | +63.9% |
| Earliest and lowest weekly close in our records · 14 Oct 2016 | ₹132.00 | +218.1% |
| Highest weekly close since October 2016 · 6 Nov 2020 | ₹1,844.95 | −77.2% |
| 52-week high (weekly close) · 1 Oct 2026 | ₹478.35 | −12.2% |
| 52-week low (weekly close) · 13 Mar 2026 | ₹207.55 | +102.3% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (534 weekly closes from 14 October 2016 to 3 November 2026.)

## What is the latest news on Valiant Organics? 3 Nov 2026: Valiant Organics closed at ₹419.95, up 1.7% on the week and down 12.2% on the month. Our read, 10 Oct 2026: A chemical intermediates maker that lost two-thirds of its profit to Chinese dumping is printing its first full-utilization-style quarter on a plant base it no longer has to build - real operating leverage, one quarter old, with a guidance record that demands proof. ### Earlier

- Results for April to June 2026: Revenue up 13.7% and profit up 262.5% on a year earlier. - 10 Nov 2023: Valiant Organics held its results call for July to September 2023. ### Our read of the business

June 2026 quarter: revenue ₹232 crore (+13.7%), operating profit ₹42 crore (+68%), operating margin 18%, profit ₹29 crore - core pre-tax profit excluding other income tripled to ₹26 crore.,The plants were built in FY20-FY23 and capital spending has run at maintenance level for three years, so extra volume drops straight to profit; gross margin rose to about 42% on a raw-material spread.,Against it: revenue is still 36% below FY22, other income was 30% of pre-tax profit, every dated 2023 promise was missed, and the free cash went into a loss-making associate rather than debt. Latest quarter: Operating profit ₹42 crore at an 18% margin - the first quarter that looks like a working business. (Our read after the latest results, written 10 October 2026.)

## What dividend does Valiant Organics pay? Valiant Organics paid no dividend in the 12 months to 4 November 2026. The last was an interim dividend of ₹1 a share, ex-date 10 February 2023. ### Valiant Organics dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 10 Feb 2023 | ₹1 | Interim | same day |
| 20 Sep 2022 | ₹3.50 | Dividend | 21 Sep 2022 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 1 of 5 Of the last 5 financial years, years with an NSE dividend record

Not in its latest year. Valiant Organics Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 10 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Valiant Organics management say on the latest results call? On the call for July to September 2023, held on 10 November 2023, Valiant Organics' management spoke about the quarter; the main points are below. Source: [the call transcript](https://files.tijorifinance.com/insight/india/6936/Conference Call/CC-Sep23.pdf). (From the call for July to September 2023, 10 November 2023. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What is the future of Valiant Organics? What is changing in the business? What is changing at Valiant Organics, from the latest results and calls: operating leverage on a finished, underused plant base, raw-material spread widening (gross margin 35% to about 42%) and lower interest cost. - Operating leverage on a finished, underused plant base. Revenue up ₹28 crore year on year in the June quarter lifted operating profit ₹17 crore - fixed costs were paid for in FY20-FY23 and capital spending now runs near maintenance level. ⚠ estimate
- Raw-material spread widening (gross margin 35% to about 42%). Gross margin has run 38-45% for five quarters versus 35% in March 2025, while management describes the period as one of pricing pressure - a spread gain on lower inputs. ⚠ estimate
- Lower interest cost. Quarterly interest fell from ₹8 crore (September 2024) to ₹3-5 crore, and nine-month finance cost fell 22%, even though total borrowings stayed near ₹256 crore. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the latest results, written 10 October 2026.)

## What could change the Valiant Organics story? What are the risks? The September 2026 quarter printing operating profit below ₹30 crore or an operating margin below 14% on revenue under ₹200 crore - that would mark June 2026 as a one-quarter spread spike, not a turn. ### Each change stops working if

- Operating leverage on a finished, underused plant base: Quarterly revenue falls back below ₹180 crore, as it did in September and December 2025, which pulled the operating margin to 8-13%. - Raw-material spread widening (gross margin 35% to about 42%): Gross margin drops below 38% for a quarter, which would show input prices catching up with realised prices. ### The main risks

- One-quarter spike - persistence unproven: Profit by quarter since September 2025 was ₹6, 4, 16 and 29 crore; the latest is 3.6 times the prior median and 30% of its pre-tax profit was other income of unknown source. ⚠ estimate
- Guidance credibility - every dated 2023 promise missed: FY24 revenue guidance went from ₹1,200 crore to ₹800-850 crore to the lower end of ₹800 crore in six months, and FY24 printed ₹723 crore at a 5% margin; the FY25 revival and FY26 term-loan repayment also slipped. ⚠ estimate
- Chinese dumping and weak agrochemical and dye demand return: In 2023 Chinese dumping cut prices 25-30% and volumes about 30% in the company's main chemistries; nothing in our corpus says that pressure has ended. ✓ fact
- Receivables build: Debtor days rose from 90 to 120 in FY26 while payable days fell from 119 to 102, widening the cash cycle from 42 to 96 days. ⚠ estimate

(Our read after the latest results, written 10 October 2026.)

## What to watch in Valiant Organics' next results? When Valiant Organics reports July to September 2026, these are the 5 checks that show whether the story is still on course. First: September 2026 quarter operating profit (needs ₹30 crore or more) and other income (should be under 20% of pre-tax profit)

| What to check | Why |
| --- | --- |
| September 2026 quarter operating profit (needs ₹30 crore or more) and other income (should be under 20% of pre-tax profit) | One-quarter spike - persistence unproven |
| Any new numeric guidance in the next results call, and whether the following two quarters meet it. | Guidance credibility - every dated 2023 promise missed |
| Quarterly revenue below ₹180 crore together with gross margin below 38%. | Chinese dumping and weak agrochemical and dye demand return |
| FY27 debtor days (should fall back toward 90-100) | Receivables build |
| A results call transcript for the June or September 2026 quarter entering the corpus. | Thin disclosure and no institutional owners |

## Which stock lists is Valiant Organics on? Valiant Organics is on 3 of our India lists: Multibagger study list, Undervalued stocks and Momentum stocks. - [Multibagger study list Study stage: early](https://www.sectoralpha.in/multibagger-stocks-india)
- [Undervalued stocks Profit growth x: 11](https://www.sectoralpha.in/markets/in/deep-value-stocks)
- [Momentum stocks Market cap cr: 1207.4514586322334](https://www.sectoralpha.in/momentum-stocks-india)

## Is Valiant Organics profitable? Valiant Organics Ltd earned ₹29.0 Cr of net profit in the Jun 2026 quarter, +262.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹33.0 Cr. Over 10 years profit has grown 12.7% a year on average. That is 12.5% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr. 4 of the last 12 reported quarters were loss-making. Why profit moved: revenue changed +13.7% on a year earlier and the margin moved +6.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +180.8% and revenue +0.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Valiant Organics make, and is it growing? Valiant Organics Ltd reported ₹232 Cr of revenue in the Jun 2026 quarter, +13.7% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 30.4% a year on average. The last full year, FY26, came in at ₹739 Cr. Why this happened. The input-cost pass-through test says this is a spread, not pricing power: nine-month gross margin rose to 43% from 38% while revenue was flat and the third quarter saw pricing pressure and soft demand. The supply side that hurt in 2023 - Chinese dumping that cut prices 25-30% - has not been reported as reversed in our corpus, so the capital-cycle consolidation model cannot be claimed. The gain is real in the numbers and is the second reason operating margin rose, but it can reverse when benzene and chlorine-chain inputs turn. The last four reported quarters add to ₹766 Cr. FY26 revenue was ₹739 Cr, +2.8% on the year before. Recent pace: the last four quarters grew +0.9% on average, against 30.4% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +1.5%, against +5.4% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does Valiant Organics keep? Valiant Organics Ltd's operating margin was 18.0% in the Jun 2026 quarter, 6.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 5.0% and 30.0%. The latest quarter is within that range. Why this happened. This is the operating-leverage catapult in its textbook setting: utilization was 55-60% in late 2023, fixed assets had grown from Rs 276 crore to about Rs 695 crore, and work in progress has fallen from Rs 86 crore to Rs 21 crore, so the capex inflection point has passed. When revenue reached Rs 218-232 crore in the March and June 2026 quarters, operating margin moved to 12% and then 18%. Who keeps the benefit: the company, as long as rivals (mainly Chinese exporters) do not cut prices again. Benefit delivered: one quarter at an 18% margin. Benefit remaining: revenue is still 36% below FY22, so there is room if demand returns, but there is no company guidance on volumes after 2023. The…

Why the margin moved: operating margin changed +5.8 percentage points on the year while gross margin changed +3.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Valiant Organics' profit turning into cash? Over the last 3 years, 113% of Valiant Organics Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹92.0 Cr of operating cash against ₹33.0 Cr of profit. After ₹33.0 Cr of spending on assets, ₹59.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 113% of profit came in as cash: the cash cycle got 51 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Valiant Organics' cash go? Valiant Organics Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 96 days in FY26, up from 45 days in FY21. It spent ₹86.0 Cr on assets over the last 3 years. Customers take 120 days to pay, and stock sits for 77 days on average. At FY26 sales of ₹739 Cr, each day of that cycle ties up about ₹2.0 Cr, so roughly ₹194 Cr is tied up in the business at any time. FY26: customers took 120 days to pay and stock sat for 77 days, about 2.5 months of sales sitting as stock, for a full cycle of 96 days, longer than FY21's 45. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 77 days. Customers pay about 120 days after that. Suppliers are paid at 102 days. Together that makes the 96-day cycle. Spending on assets: ₹86.0 Cr over the last 3 years, against ₹111 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹21.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Valiant Organics' P/E ratio, and how does it compare with its own history? Valiant Organics Ltd's P/E is 23.3×, in the middle of its own history: higher than 53% of past readings. Its usual P/E (the middle reading) is 21.9×, over 7.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹19.29. Where the price move came from: over 5 years the price moved −20.6% a year; about −15.2% a year came from earnings growth and about −5.4 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 20% on reported income across 16 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What growth does the Valiant Organics share price assume? Worked out from its price on 11 October 2026, Valiant Organics Ltd's share price assumed profit growth of about 17.0% a year. Over the past 10 years its profit actually grew 12.7% a year. Today its P/E is 23.3×, higher than 53% of its own last 7.1 years. This is a one-day reading, taken on 11 October 2026. Every other number on this page, the multiple included, uses the latest price as of 3 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Valiant Organics business getting better or worse? Valiant Organics Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 3 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## What is the Valiant Organics story, and has it been checked? Valiant Organics Ltd's story is not scored yet against the checks our research set on 10 October 2026. Where it sits in its own cycle: EARLY RECOVERY. Our read, 10 October 2026. A chemical intermediates maker that lost two-thirds of its profit to Chinese dumping is printing its first full-utilization-style quarter on a plant base it no longer has to build - real operating leverage, one quarter old, with a guidance record that demands proof. From the numbers. From the price. Price stage 2, week 9, above its 200-day line, relative strength rising. From the research. A chemical intermediates maker that lost two-thirds of its profit to Chinese dumping is printing its first full-utilization-style quarter on a plant base it no longer has to build - real operating leverage, one quarter…

Where they disagree. Operating margin is at the 62nd percentile, well below the 31.7% high, so this is an early recovery, not a peak. What is proven. A chemical intermediates maker that lost two-thirds of its profit to Chinese dumping is printing its first full-utilization-style quarter on a plant base it no longer has to build - real operating leverage, one quarter old, with a guidance record that demands proof. What is not proven yet. The September 2026 quarter printing operating profit below Rs 30 crore or an operating margin below 14% on revenue under Rs 200 crore - that would mark June 2026 as a one-quarter spread spike, not a turn. What would change our mind. The September 2026 quarter printing operating profit below Rs 30 crore or an operating margin below 14% on revenue under Rs 200 crore - that would mark June 2026 as a one-quarter spread spike, not a turn. The test written in advance. The September 2026 quarter printing operating profit below Rs 30 crore or an operating margin below 14% on revenue under Rs 200 crore - that would mark June 2026 as a one-quarter spread spike, not a turn. Measured by: the thesis as written as stated by the next result. The test written in advance. One-quarter spike - persistence unproven. Measured by: One-quarter spike - persistence unproven by the next result. The test written in advance. Guidance credibility - every dated 2023 promise missed. Measured by: Guidance credibility - every dated 2023 promise missed Any new numeric guidance in the next results call, and whether the following two quarters meet it by the next result. What the company does. June 2026 quarter: revenue Rs 232 crore (+13.7%), operating profit Rs 42 crore (+68%), operating margin 18%, profit Rs 29 crore - core pre-tax profit excluding other income tripled to Rs 26 crore. The plants were built in FY20-FY23 and capex has run at maintenance level for three years, so extra volume drops straight to profit; gross margin rose to about 42% on a raw-material spread. Against it: revenue is still 36% below FY22, other income was 30% of pre-tax profit, every dated 2023 promise was missed, and the free cash went into a loss-making associate rather than debt. What the surface reading misses. The surface reading is: Profit up 262% in one quarter - earnings are taking off. The research reads it further: Most of the jump is operating, not other income. Operating profit rose Rs 17 crore (42 vs 25) on only Rs 28 crore more revenue, so about 60% of the extra sales dropped to operating profit - the fixed costs of a plant base built in 2020-23 are already paid for. Interest also fell (Rs 5 crore vs Rs 8 crore in September 2024). But other income of Rs 11 crore is 30% of pre-tax profit and its source is not disclosed, and this is one quarter: the run since September 2025 is Rs 6, 4, 16 and 29 crore of profit. What the surface reading misses. The surface reading is: Gross margin up about 7 points in a year - pricing power has returned. The research reads it further: The input-cost pass-through test reads two ways here. Gross margin jumped while revenue was flat to down (FY26 revenue +2.8%), which in a commodity intermediate business usually means raw material prices (benzene, phenol, chlorine derivatives) fell faster than realised prices, not that customers accepted higher prices. Management's own words for the nine months were margin expansion 'despite near-term pricing pressures' and a third quarter with 'pricing pressure and demand softness'. So the gross line is a spread gain, which can reverse when inputs turn. Lever 1 · Operating leverage: building. Revenue up Rs 28 crore year on year in the June quarter lifted operating profit Rs 17 crore - fixed costs were paid for in FY20-FY23 and capex now runs near maintenance level. What proves it keeps working: Operating leverage on a finished, underused plant base. It stops working if Quarterly revenue falls back below Rs 180 crore, as it did in September and December 2025, which pulled the operating margin to 8-13%. Lever 7 · Consolidation: building. Gross margin has run 38-45% for five quarters versus 35% in March 2025, while management describes the period as one of pricing pressure - a spread gain on lower inputs. What proves it keeps working: Raw-material spread widening (gross margin 35% to about 42%). It stops working if Gross margin drops below 38% for a quarter, which would show input prices catching up with realised prices. Lever 4 · Paying down debt: building. Quarterly interest fell from Rs 8 crore (September 2024) to Rs 3-5 crore, and nine-month finance cost fell 22%, even though total borrowings stayed near Rs 256 crore. What proves it keeps working: Lower interest cost. Sources: our stock research file (10 October 2026) · quarterly results through Jun 2026. The story check is re-scored every results season; the record below never changes. ## What is Valiant Organics management's track record? The old SEBI disclosure case was settled without admitting or denying findings; no live fraud or conduct case is established. The tax rectification is a separate disclosure, not evidence of dishonesty. Sources:

- [valiantorganics.com](https://www.valiantorganics.com/assets/investors/annual-report-2025-26.pdf)
- [legal.economictimes.indiatimes.com](https://legal.economictimes.indiatimes.com/news/regulators/valiant-organics-settles-case-with-sebi-pays-rs-10-lakh/103840736)
- [valiantorganics.com](https://www.valiantorganics.com/assets/investors/shareholding-pattern-march-2026.pdf)

(Checked 14 October 2026.)

## How much does Valiant Organics earn on its capital? Valiant Organics Ltd earned a ROCE of 5% in FY26. That is up from a low of 1% in FY24. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 4.5% net margin and 0.60× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 4.5% net margin × 0.60× asset turnover × 1.62× leverage (assets divided by equity) ≈ 4.4% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 20% on reported income across 16 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Valiant Organics have too much debt? Valiant Organics Ltd had ₹256 Cr of borrowings against ₹759 Cr of equity in FY26, so its debt is 0.34× its equity. Its operating profit is 5 times its interest bill. Over 5 years borrowings went from ₹209 Cr to ₹256 Cr. Over the last 3 of those years it spent ₹86.0 Cr on assets. Why this happened. Term loans are being repaid (non-current borrowings Rs 74.2 crore to Rs 38.9 crore), which is visible in the quarterly interest line. Total borrowings did not fall because short-term working-capital debt stayed, and the FY26 free cash went into the associate. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 20% on reported income across 16 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Valiant Organics shareholding pattern? No group of Valiant Organics Ltd's owners changed its stake by a full percentage point over the last two years. Promoters moved +0.1 points over the same period, to 37.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −0.9 points over 8 quarters, to 0.4%; Promoters: +0.1 points over 8 quarters, to 37.9%; Domestic institutions: −0.1 points over 8 quarters, to 0.0%. ## How far is Valiant Organics from balance-sheet trouble? For Valiant Organics Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Valiant Organics rank in its industry? 61.1 out of 100, rank 3 of 20 in Chemicals - Organic, with 78% of the evidence available. Valiant Organics Ltd scores 61.1 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 3. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.4 + 9 + 10.9 + 19.8 = 61.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Valiant Organics compared with? Valiant Organics ranks 3 of 20 Chemicals - Organic companies on the 4-Factor Sector Score, with 61.1 out of 100. 1. [Nitta Gelatin India Ltd](https://www.sectoralpha.in/stocks/nitta-gelatin-india-ltd) NITTAGELA · quiet · Most evidence points up · 85% evidence 76.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.4/35 · Revenue 15% · Profit 49.4% · Operating margin change 9 points · 100% evidence Capital efficiency 21.3/25 · ROCE 27.7% · Operating margin 28% · 100% evidence Valuation 13.2/20 · P/E 12.1× · PEG 0.95 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 35.5% · 1 year n/a · 25% evidence · 5 of 12 weeks ahead Exact sum: 30.4 + 21.3 + 13.2 + 12 = 76.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) INDOAMIN · losing its lead · Most evidence points up · 81% evidence 66.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 13.3% · Profit 24.2% · Operating margin change 3 points · 88% evidence Capital efficiency 16.8/25 · ROCE 18.9% · Operating margin 14% · 100% evidence Valuation 19.0/20 · P/E 10.6× · PEG 0.32 · 100% evidence Relative strength 9.5/20 · Lead over its industry n/a · Lead over NIFTY 500 2.3% · 1 year -10.4% · 25% evidence · 4 of 12 weeks ahead Exact sum: 20.8 + 16.8 + 19 + 9.5 = 66.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. Valiant Organics Ltd this page VALIANTORG · breaking out · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 1.5% · Profit 100% · Operating margin change 6 points · 83% evidence Capital efficiency 9.0/25 · ROCE 5.5% · Operating margin 18% · 76% evidence Valuation 10.9/20 · P/E 23.2× · PEG n/a · 50% evidence Relative strength 19.8/20 · Lead over its industry 24.1% · Lead over NIFTY 500 48.6% · 1 year 39.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.4 + 9 + 10.9 + 19.8 = 61.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [OCCL Ltd](https://www.sectoralpha.in/stocks/occl-ltd) OCCLLTD · breaking out · Too little evidence to rank firmly · 56% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 40.6% · Profit 100% · Operating margin change 7 points · 83% evidence Capital efficiency 12.3/25 · ROCE 13% · Operating margin 28% · 76% evidence Valuation 11.1/20 · P/E 11× · PEG n/a · 15% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 45.3% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.6 + 12.3 + 11.1 + 12.1 = 59.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) BASF · quiet · Evidence leans up · 71% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 6.5% · Profit 62.4% · Operating margin change 4 points · 88% evidence Capital efficiency 11.7/25 · ROCE 14.5% · Operating margin 10% · 100% evidence Valuation 14.1/20 · P/E 21.4× · PEG n/a · 50% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -13% · 1 year -30.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 23.8 + 11.7 + 14.1 + 7.7 = 57.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Elantas Beck India Ltd](https://www.sectoralpha.in/stocks/elantas-beck-india-ltd) ELANTAS · leader · Evidence leans up · 67% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 18.7% · Profit 35.5% · Operating margin change 1 points · 95% evidence Capital efficiency 18.1/25 · ROCE 21.2% · Operating margin 23% · 76% evidence Valuation 6.5/20 · P/E 54.1× · PEG n/a · 50% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 31.9% · 1 year 33.1% · 25% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 18.1 + 6.5 + 11.8 = 57.1 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 7. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) FINEORG · leader · Evidence leans up · 96% evidence 56.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue 7.1% · Profit 5.8% · Operating margin change 4 points · 88% evidence Capital efficiency 17.8/25 · ROCE 21.5% · Operating margin 25% · 100% evidence Valuation 15.0/20 · P/E 35.3× · PEG 0.58 · 100% evidence Relative strength 9.9/20 · Lead over its industry -7.6% · Lead over NIFTY 500 12.4% · 1 year 13.8% · 100% evidence · 9 of 12 weeks ahead Exact sum: 13.9 + 17.8 + 15 + 9.9 = 56.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 8. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) LXCHEM · quiet · Evidence leans up · 81% evidence 54.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 5.5% · Profit 26% · Operating margin change 7.6 points · 88% evidence Capital efficiency 10.8/25 · ROCE 4.7% · Operating margin 12% · 100% evidence Valuation 13.1/20 · P/E 33.8× · PEG 1.14 · 100% evidence Relative strength 9.2/20 · Lead over its industry n/a · Lead over NIFTY 500 1.8% · 1 year -22% · 25% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 10.8 + 13.1 + 9.2 = 54.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Balaji Amines Ltd](https://www.sectoralpha.in/stocks/balaji-amines-ltd) BALAMINES · quiet · Evidence leans up · 78% evidence 53.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.2/35 · Revenue 11.1% · Profit 41.6% · Operating margin change 10 points · 83% evidence Capital efficiency 13.1/25 · ROCE 11% · Operating margin 25% · 76% evidence Valuation 9.1/20 · P/E 28× · PEG n/a · 50% evidence Relative strength 8.2/20 · Lead over its industry -2.5% · Lead over NIFTY 500 15.2% · 1 year 25.3% · 100% evidence · 6 of 12 weeks ahead Exact sum: 23.2 + 13.1 + 9.1 + 8.2 = 53.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) FAIRCHEMOR · quiet · Evidence leans up · 100% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 17.1% · Profit 100% · Operating margin change 6.2 points · 100% evidence Capital efficiency 7.0/25 · ROCE 3.3% · Operating margin 10% · 100% evidence Valuation 13.0/20 · P/E 32.7× · PEG 0.84 · 100% evidence Relative strength 3.0/20 · Lead over its industry -15.4% · Lead over NIFTY 500 3.2% · 1 year -15.9% · 100% evidence · 9 of 12 weeks ahead Exact sum: 30.3 + 7 + 13 + 3 = 53.3 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -15.9%. 11. [Sigachi Industries Ltd](https://www.sectoralpha.in/stocks/sigachi-industries-ltd) SIGACHI · breaking out · Evidence leans down · 100% evidence 49.4 out of 100 Growth Capital Valuation Relative
12. [GFL Ltd](https://www.sectoralpha.in/stocks/gfl-ltd) GFLLIMITED · breaking out · Evidence leans down · 71% evidence 48.6 out of 100 Growth Capital Valuation Relative
13. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) JYOTIRES · basing · Evidence leans down · 74% evidence 43.7 out of 100 Growth Capital Valuation Relative
14. [Foseco India Ltd](https://www.sectoralpha.in/stocks/foseco-india-ltd) FOSECOIND · leader · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
15. [Shree Ganesh Remedies Ltd](https://www.sectoralpha.in/stocks/shree-ganesh-remedies-ltd) SGRL · breaking out · Evidence leans down · 85% evidence 40.3 out of 100 Growth Capital Valuation Relative
16. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) OAL · leader · Evidence leans down · 74% evidence 36.5 out of 100 Growth Capital Valuation Relative
17. [Gem Aromatics Ltd](https://www.sectoralpha.in/stocks/gem-aromatics-ltd) GEMAROMA · quiet · Too little evidence to rank firmly · 51% evidence 32.2 out of 100 Growth Capital Valuation Relative
18. [Sacheerome Ltd](https://www.sectoralpha.in/stocks/sacheerome-ltd) SACHEEROME · losing its lead · Too little evidence to rank firmly · 36% evidence 58.1 out of 100 Growth Capital Valuation Relative
19. [Shri Ahimsa Naturals Ltd](https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd) SHRIAHIMSA · leader · Too little evidence to rank firmly · 47% evidence 56.8 out of 100 Growth Capital Valuation Relative
20. [Citurgia Biochemicals Ltd](https://www.sectoralpha.in/stocks/citurgia-biochemicals-ltd) CITURGIA · Too little evidence to rank firmly · 25% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Organic](https://www.sectoralpha.in/sectors/chemicals-organic), all 20 compared on one page. ## Which companies are close to Valiant Organics in size? Valiant Organics is the 15th largest of 20 Chemicals - Organic companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Shri Ahimsa Naturals, Sacheerome and Indo Amines. Just below it: OCCL, Fairchem Organics and Shree Ganesh Remedies. ### Chemicals - Organic companies close in size

1. [Shri Ahimsa Naturals Ltd](https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd) ₹952 crore
2. [Sacheerome Ltd](https://www.sectoralpha.in/stocks/sacheerome-ltd) ₹922 crore
3. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) ₹865 crore
4. Valiant Organics Ltd ₹864 crore
5. [OCCL Ltd](https://www.sectoralpha.in/stocks/occl-ltd) ₹841 crore
6. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) ₹801 crore
7. [Shree Ganesh Remedies Ltd](https://www.sectoralpha.in/stocks/shree-ganesh-remedies-ltd) ₹792 crore

[All 20 Chemicals - Organic companies, largest first](https://www.sectoralpha.in/sectors/chemicals-organic#all-companies)

### Companies close in size in other industries

1. [Synergy Green Industries Ltd](https://www.sectoralpha.in/stocks/synergy-green-industries-ltd) ₹866 crore · Castings, Forgings & Fastners
2. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) ₹865 crore · Chemicals - Organic
3. Valiant Organics Ltd ₹864 crore
4. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) ₹862 crore · Pesticides/Agrochemicals
5. [One Global Service Provider Ltd](https://www.sectoralpha.in/stocks/one-global-service-provider-ltd) ₹858 crore · Diagnostics

## What else do people ask about Valiant Organics? ### What is Valiant Organics's share price today? Valiant Organics Ltd's share price is ₹419.95, +39.7% over the past year. The whole company is worth ₹1,177 Cr on the market. In the last 52 weeks it traded between ₹208 to ₹478; today it is 78% of the way up from the low, 26.7% above its 200-day average (as of 3 November 2026). ### What were Valiant Organics's latest quarterly results? Valiant Organics Ltd reported revenue of ₹232 Cr and net profit of ₹29.0 Cr for the Jun 2026 quarter. Revenue rose 13.7% and profit rose 262.5% compared with a year earlier. Earnings per share were ₹10.36. The operating margin was 18.0%, 6.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Valiant Organics's market cap? Valiant Organics Ltd's market capitalisation is ₹1,177 Cr at a share price of ₹419.95. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Valiant Organics performing? Valiant Organics Ltd's share price has been rising for 9 weeks. In its latest quarter, revenue rose 13.7% and profit rose 262.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 11 weeks running (as of 3 November 2026). ### Will Valiant Organics's share price go up? This page does not forecast Valiant Organics Ltd's share price. What it shows instead: the share price is ₹419.95, and it has been rising for 9 weeks. Its P/E of 23.3× is higher than 53% of its own last 7 years (as of 3 November 2026). ### Who owns Valiant Organics? Promoters own 37.9% of Valiant Organics Ltd, foreign institutions 0.4%, domestic institutions 0.0% and the public 61.6% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 3 November 2026). ### Where is Valiant Organics in its business cycle? Valiant Organics Ltd's FY26 operating margin was 12.0%, against a 13-year range of 5.0% to 30.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 18.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Valiant Organics story? Biggest thing to watch: the price has already been rising for 9 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Valiant Organics a stock worth studying right now? What the numbers show: Valiant Organics Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Valiant Organics share price forecast for 2026? What is changing at Valiant Organics, from the latest results and calls: operating leverage on a finished, underused plant base, raw-material spread widening (gross margin 35% to about 42%) and lower interest cost. What would change the story: The September 2026 quarter printing operating profit below ₹30 crore or an operating margin below 14% on revenue under ₹200 crore - that would mark June 2026 as a one-quarter spread spike, not a turn. ### Where does this page get Valiant Organics' management information? From Valiant Organics' results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists

- Multibagger study list: https://www.sectoralpha.in/multibagger-stocks-india
- Undervalued stocks: https://www.sectoralpha.in/markets/in/deep-value-stocks
- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india

This is research, not advice. We’re not SEBI-registered.